Media headlines about Cipher Pharmaceuticals (NASDAQ:CPHR) (TSE:CPH) have been trending somewhat positive on Monday, Accern Sentiment reports. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cipher Pharmaceuticals earned a news sentiment score of 0.05 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 44.4446637112034 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Cipher Pharmaceuticals (NASDAQ:CPHR) remained flat at $2.99 during mid-day trading on Monday. Cipher Pharmaceuticals has a 12-month low of $2.55 and a 12-month high of $5.25. The firm has a 50-day moving average price of $2.99 and a 200-day moving average price of $2.99.
About Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA.
Receive News & Ratings for Cipher Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
